A possibility of nutriceuticals as an anti-aging intervention: activation of sirtuins by promoting mammalian NAD biosynthesis

Pharmacol Res. 2010 Jul;62(1):42-7. doi: 10.1016/j.phrs.2010.01.006. Epub 2010 Jan 18.


Aging science has recently drawn much attention, and discussions on the possibility of anti-aging medicine have multiplied. One potential target for the development of anti-aging drugs is the SIR2 (silent information regulator 2) family of NAD-dependent deacetylases/ADP-ribosyltransferases, called "sirtuins." Sirtuins regulate many fundamental biological processes in response to a variety of environmental and nutritional stimuli. In mammals, the mammalian SIR2 ortholog SIRT1 has been most studied, and small molecule SIRT1 activators (STACs), including a plant-derived polyphenolic compound resveratrol, have been developed. On the other hand, sirtuin activity is regulated by NAD biosynthetic pathways, and nicotinamide phosphoribosyltransferase (NAMPT) plays a critical role in the regulation of mammalian sirtuin activity. Recent studies have provided a proof of concept for the idea that nicotinamide mononucleotide (NMN), the NAMPT reaction product, can be used as a nutriceutical to activate SIRT1 activity. Based on these recent findings, the possibility of sirtuin-targeted nutriceutical development will be discussed.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Aging / drug effects*
  • Aging / metabolism
  • Animals
  • Drug Design
  • Enzyme Activation
  • Flavonoids / pharmacology*
  • Humans
  • NAD / biosynthesis*
  • Nicotinamide Mononucleotide / pharmacology*
  • Nicotinamide Phosphoribosyltransferase / physiology
  • Phenols / pharmacology*
  • Polyphenols
  • Sirtuins / metabolism*
  • Small Molecule Libraries / pharmacology*


  • Flavonoids
  • Phenols
  • Polyphenols
  • Small Molecule Libraries
  • NAD
  • Nicotinamide Mononucleotide
  • Nicotinamide Phosphoribosyltransferase
  • Sirtuins